Loading...
XSHG
600557
Market cap1.22bUSD
Dec 05, Last price  
15.21CNY
1D
0.73%
1Q
-11.00%
Jan 2017
-10.16%
IPO
600.92%
Name

Jiangsu Kanion Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHG:600557 chart
P/E
21.98
P/S
2.21
EPS
0.69
Div Yield, %
2.45%
Shrs. gr., 5y
-0.57%
Rev. gr., 5y
-3.11%
Revenues
3.90b
-19.93%
802,419,230852,699,626998,634,6671,132,031,391968,532,6931,358,307,6491,537,777,5981,903,373,7022,230,302,8672,562,928,2432,820,446,2843,000,277,8073,274,698,1533,823,804,7354,565,798,0043,031,926,3563,648,570,0844,350,871,9224,867,806,7023,897,669,000
Net income
392m
-26.99%
48,844,62264,022,58596,357,706141,940,085160,268,157180,728,871182,508,139239,671,216297,017,573319,614,208362,336,257373,740,970373,782,724431,386,148506,993,260262,922,648320,543,630434,467,433536,732,878391,862,000
CFO
702m
-33.46%
101,436,378108,980,98392,733,80658,389,0790166,399,11490,186,765212,108,112388,106,244311,543,597514,795,720299,017,699382,928,707636,392,894925,725,534701,103,454908,295,889995,939,9921,055,799,495702,488,000
Dividend
May 31, 20240.37203 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Jiangsu Kanion Pharmaceutical Co.,Ltd. researches and develops, produces, and sells Chinese medicines. It offers medicines in the fields of gynecology, orthopedics, antiviral, cardio cerebrovascular, and other fields. The company was founded in 1975 and is based in Lianyungang, China.
IPO date
Sep 18, 2002
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT